CSL Behring And SAB Explore Polyclonal Antibodies For COVID-19
Clinical trials Could Start By This Summer
CSL Behring is backing the US biotech SAB Biotherapeutics in developing polyclonal antibodies in cattle for their efficacy against the pandemic virus, adding a second strand to the research efforts of the blood products specialty company.
